1887

Journal of Medical Microbiology logo

Volume 69, Issue 1

Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model Free

Abstract

Nanoparticles (NPs) have numerous biological benefits due to their large surface-volume ratio and convenient entry into cells compared to other particles. Previous research has shown the antimicrobial properties of biogenic selenium NPs (SeNps) and their effects on cellular immunomodulatory cytokines that play a key role in controlling infections.

This study aimed to evaluate the therapeutic effects of SeNPs against chronic toxoplasmosis in mice.

Infected mice with (Tehran strain) were orally treated with SeNPs at doses of 2.5, 5 and 10 mg kg once a day for 14 days. On the fifthteenth day, the mean number of brain-tissue cysts and the mRNA levels of TNF-α, IL-12, IL-10, IFN-γ and inducible nitric oxide synthase (iNOS) in the mice of each group were recorded. Moreover, serum clinical chemistry factors in the treated mice were examined to determine the safety of SeNPs.

The mean number of tissue cysts was significantly (<0.001) decreased in mice treated with SeNPs in a dose-dependent manner compared with the control group. The mRNA levels of inflammatory cytokines were significantly increased in mice treated with SeNPs at a dose of 10 mg kg compared with the control subgroup (<0.05). No significant variation (>0.05) observed in clinical chemistry parameters among the mice in the control subgroup compared with those treated with SeNPs.

The findings demonstrated the therapeutic effects of SeNPs with no considerable toxicity against latent toxoplasmosis in the mouse model. Nevertheless, further studies are obligatory to reveal the exact anti-Toxoplasma mechanisms of SeNPs.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): cytokine , mice , nanoparticles , toxicity and toxoplasmosis
© 2020 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001111
2020-01-01
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/1/104.html?itemId=/content/journal/jmm/10.1099/jmm.0.001111&mimeType=html&fmt=ahah

References

  1. Dubey JP. Toxoplasmosis - a waterborne zoonosis. Vet Parasitol 2004; 126:57–72 [View Article]
     [Google Scholar]
  2. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 2002; 8:634–640 [View Article]
     [Google Scholar]
  3. Khryanin AA, Reshetnikov OV, Kuvshinova IN. Toxoplasmosis: epidemiology, diagnosis, treatment. Antibiot Khimioter 2015; 60:16–21
     [Google Scholar]
  4. Lewis JM, Clifford S, Nsutebu E. Toxoplasmosis in immunosuppressed patients. Rheumatology 2015; 54:1939–1940 [View Article]
     [Google Scholar]
  5. Antczak M, Dzitko K, Długońska H. Human toxoplasmosis-searching for novel chemotherapeutics. Biomed Pharmacother 2016; 82:677–684 [View Article]
     [Google Scholar]
  6. Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis 2012; 44:805–814
     [Google Scholar]
  7. Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human toxoplasmosis: a systematic review. Pathog Glob Health 2017; 111:333–342
     [Google Scholar]
  8. Alday PH, Doggett JS. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther 2017; 11:273–293 [View Article]
     [Google Scholar]
  9. Hoffmann PR, Berry MJ. Prophylaxis of human toxoplasmosis: a systematic review. Mol Nutr Food Res 2008; 52:1273–1280
     [Google Scholar]
  10. Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E et al. A Systematic Review of In vitro and In vivo activities of anti-Toxoplasma drugs and compounds (2006-2016) . Front Microbiol 2017; 8:25–32 [View Article]
     [Google Scholar]
  11. Shakibaie M, Khorramizadeh MR, Faramarzi MA, Sabzevari O, Shahverdi AR. Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. Biotechnol Appl Biochem 2010; 56:7–15 [View Article]
     [Google Scholar]
  12. Rayman MP. The importance of selenium to human health. The Lancet 2000; 356:233–241 [View Article]
     [Google Scholar]
  13. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005; 64:527–542 [View Article]
     [Google Scholar]
  14. Whanger PD. Selenium and its relationship to cancer: an update. Br J Nutr 2004; 91:11–28 [View Article]
     [Google Scholar]
  15. Kojouri GA, Jahanabadi S, Shakibaie M, Ahadi AM, Shahverdi AR. Effect of selenium supplementation with sodium selenite and selenium nanoparticles on iron homeostasis and transferrin gene expression in sheep: a preliminary study. Res Vet Sci 2012; 93:275–278 [View Article]
     [Google Scholar]
  16. Tran PA, Webster TJ. Selenium nanoparticles inhibit Staphylococcus aureus growth. Int J Nanomedicine 2011; 6:1553–1558 [View Article]
     [Google Scholar]
  17. Yang J, Huang K, Qin S, Wu X, Zhao Z et al. Antibacterial action of selenium-enriched probiotics against pathogenic Escherichia coli . Dig Dis Sci 2009; 54:246–254 [View Article]
     [Google Scholar]
  18. Mézes M, Balogh K. Prooxidant mechanisms of selenium toxicity – a review. Acta Biologica Szegediensis 2009; 53:15–18
     [Google Scholar]
  19. Beheshti N, Soflaei S, Shakibaie M, Yazdi MH, Ghaffarifar F et al. Efficacy of biogenic selenium nanoparticles against Leishmania major: in vitro and in vivo studies. J Trace Elem Med Biol 2013; 27:203–207 [View Article]
     [Google Scholar]
  20. Yazdi MH, Mahdavi M, Faghfuri E, Faramarzi MA, Sepehrizadeh Z et al. Th1 immune response induction by biogenic selenium nanoparticles in mice with breast cancer: preliminary vaccine model. Iran J Biotechnol 2015; 13:1–9 [View Article]
     [Google Scholar]
  21. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol 2012; 34:793–813 [View Article]
     [Google Scholar]
  22. Zia-Ali N, Fazaeli A, Khoramizadeh M, Ajzenberg D, Dardé M et al. Isolation and molecular characterization of Toxoplasma gondii strains from different hosts in Iran. Parasitol Res 2007; 101:111–115 [View Article]
     [Google Scholar]
  23. Mahmoudvand H, Ziaali N, Aghaei I, Sheibani V, Shojaee S et al. The possible association between Toxoplasma gondii infection and risk of anxiety and cognitive disorders in BALB/c mice. Pathog Glob Health 2015; 109:369–376 [View Article]
     [Google Scholar]
  24. Mahmoudvand H, Sheibani V, Shojaee S, Mirbadie SR, Keshavarz H et al. Toxoplasma gondii Infection Potentiates Cognitive Impairments of Alzheimer's Disease in the BALB/c Mice. J Parasitol 2016; 102:629–635 [View Article]
     [Google Scholar]
  25. Saraei M, Ghaderi Y, Mosavi T, Shahnazi M, Keshavarz H et al. Brain cystogenesis capacity of Toxoplasma gondii, avirulent Tehran strain in mice. Asian Pac J Trop Dis 2014; 4:S739–S742 [View Article]
     [Google Scholar]
  26. Keyhani A, Mahmoudvand H, Shakibaie M, Tavakoli Kareshk A, Nejati J et al. Histopathological and toxicological study of selenium nanoparticles in BALB/c mice. Entomol Appl Sci Lett 2018; 5:31–35
     [Google Scholar]
  27. Ha TY, Chang KA, Kim JA, Kim HS, Kim S et al. S100A9 knockdown decreases the memory impairment and the neuropathology in Tg2576, ad animal model. PLoS One 2010; 21:e8840
     [Google Scholar]
  28. Harrell M, Carvounis PE. Current treatment of Toxoplasma retinochoroiditis: an evidence-based review. J Ophthalmol 2014; 2014:77
     [Google Scholar]
  29. Shakibaie M, Shahverdi AR, Faramarzi MA, Hassanzadeh GR, Rahimi HR et al. Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharm Biol 2013; 51:58–63 [View Article]
     [Google Scholar]
  30. Khurana A, Tekula S, Saifi MA, Venkatesh P, Godugu C. Therapeutic applications of selenium nanoparticles. Biomed Pharmacother 2019; 111:802–812 [View Article]
     [Google Scholar]
  31. Dunay IR, Heimesaat MM, Bushrab FN, Müller RH, Stocker H et al. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2004; 48:4848–4854 [View Article]
     [Google Scholar]
  32. Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii . Int J Exp Pathol 1994; 75:111–116
     [Google Scholar]
  33. Pearson A, Piracha A, Sen H, Jaffe G. Atovaquone for the treatment of Toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 1998; 106:148–153
     [Google Scholar]
  34. Schöler N, Krause K, Kayser O, Müller RH, Borner K et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2001; 45:1771–1779 [View Article]
     [Google Scholar]
  35. Yazdi MH, Varastehmoradi B, Faghfuri E, Mavandadnejad F, Mahdavi M et al. Adjuvant effect of biogenic selenium nanoparticles improves the immune responses and survival of mice receiving 4T1 cell antigens as vaccine in breast cancer murine model. J Nanosci Nanotechnol 2015; 15:10165–10172 [View Article]
     [Google Scholar]
  36. El-Ghazaly MA, Fadel N, Rashed E, El-Batal A, Kenawy SA. Anti-Inflammatory effect of selenium nanoparticles on the inflammation induced in irradiated rats. Can J Physiol Pharmacol 2017; 95:101–110 [View Article]
     [Google Scholar]
  37. Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR et al. Amelioration of experimental colitis by a novel nanoselenium–silymarin mixture. Toxicol Mech Methods 2011; 21:200–208 [View Article]
     [Google Scholar]
  38. Mahmoudvand H, Fasihi Harandi M, Shakibaie M, Aflatoonian MR, ZiaAli N et al. Scolicidal effects of biogenic selenium nanoparticles against protoscolices of hydatid cysts. Int J Surg 2014; 12:399–403
     [Google Scholar]
  39. Loomis TA. Essential of Toxicology, 4th ed. Philadelphia: Lea and Febige; 1996
     [Google Scholar]
  40. Dardé ML, Bouteille B, Pestre-Alexandre M, Darde ML, Perstre M. Isoenzyme analysis of 35 Toxoplasma gondii isolates and the biological and epidemiological implications. J Parasitol 1992; 78:786–912 [View Article]
     [Google Scholar]
  41. Dardé ML. Genetic analysis of the diversity in Toxoplasma gondii . Ann Ist Super Sanita 2004; 40:57–63
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001111
Loading
Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model
J. Med. Microbiol. 69, 104 (2020); https://doi.org/10.1099/jmm.0.001111
/content/journal/jmm/10.1099/jmm.0.001111
/content/journal/jmm/10.1099/jmm.0.001111
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error